These effects, together with a preceding report showing that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like conduct in mice,2 aid the notion of focusing on ACKR3 as a unique strategy to modulate the opioid process, which could open up new therapeutic avenues for opioid-similar di